Opinion|Videos|January 17, 2025
MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas
Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
- What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5